Karolinska Development ROA 2024

Karolinska Development Aktienanalyse

What does Karolinska Development do?

Karolinska Development AB is a Swedish investment company focused on promoting innovative biotech companies and start-ups. The company was founded in 2003 by the government of the Stockholm region and Karolinska Institutet University. The business model of Karolinska Development is designed to make profitable investments in promising biotech companies. It specifically supports companies in the areas of cancer treatment, immunotherapy, cardiovascular diseases, as well as neurology and psychiatry. The company provides capital and expertise to turn promising innovations into successful products. Karolinska Development operates different divisions to fulfill this purpose, including Karolinska Development AB (parent company), Karolinska Development Life Science Venture AB (a specialized investment company), and Karolinska Development Management AB (portfolio management team). Karolinska Development has built a strong portfolio of companies developing innovative products and therapies. One example is Modus Therapeutics AB, which has developed a new therapy for the treatment of sickle cell anemia. Another example is Aprea AB, a developer of gene therapies for combating cancer using tumor cells and genetic sequencing. The company's history is marked by many successful investments and acquisitions. One example is the acquisition of BioChromix AB in 2012, which developed a new technology for rapid and precise diagnosis of infectious diseases. Karolinska Development also actively participates in supporting new start-ups and company formations to promote promising innovations. Karolinska Development AB plays an important role in the biotech industry and significantly supports research in drug development. Through its unique position as an investor and partner for innovative companies, Karolinska Development is a driving force in the field of biotechnology. The company's business field is characterized by high risk and requires strategic thinking and skillful maneuvering in the market. However, Karolinska Development has managed to build a solid foundation and establish itself as an important player in the biotech industry through targeted investments, acquisitions, and partnerships. In summary, Karolinska Development plays a vital role in the biotech industry in Sweden and worldwide. The company has produced many innovative companies and products through targeted investments and acquisitions, contributing to changing lives and combating diseases. With its unique position as an investor and partner for biotech companies, Karolinska Development is well-equipped to continue promoting new innovations and advancing drug development in the future. Karolinska Development ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROA Details

Understanding Karolinska Development's Return on Assets (ROA)

Karolinska Development's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.

Year-to-Year Comparison

Comparing Karolinska Development's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.

Impact on Investments

Investors consider Karolinska Development's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.

Interpreting ROA Fluctuations

Variations in Karolinska Development’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.

Frequently Asked Questions about Karolinska Development stock

What is the Return on Assets (ROA) of Karolinska Development this year?

The Return on Assets (ROA) of Karolinska Development is 0 undefined this year.

What was the ROA of Karolinska Development compared to the previous year?

The ROA of Karolinska Development has increased by -106.08% compared to the previous year.

What consequences do high ROA have for investors of Karolinska Development?

A high ROA is advantageous for investors of Karolinska Development, as it indicates that the company efficiently utilizes its assets and generates good profits.

What are the consequences of low ROA for investors in Karolinska Development?

A low ROA can be unfavorable for investors of Karolinska Development as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.

How does an increase in the ROA of Karolinska Development affect the company?

An increase in ROA of Karolinska Development can be an indicator of improved efficiency in asset utilization and higher profitability.

How does a reduction in ROA of Karolinska Development impact the company?

A reduction in the ROA of Karolinska Development can be an indicator of lower asset efficiency and profitability.

What are some factors that can influence the ROA of Karolinska Development?

Some factors that can influence the ROA of Karolinska Development include revenue, operating costs, asset structure, and industry average.

Why is the ROA of Karolinska Development important for investors?

The ROA of Karolinska Development is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.

What strategic measures can Karolinska Development take to improve ROA?

To improve ROA, Karolinska Development can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.

How much dividend does Karolinska Development pay?

Over the past 12 months, Karolinska Development paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Karolinska Development is expected to pay a dividend of 0 SEK.

What is the dividend yield of Karolinska Development?

The current dividend yield of Karolinska Development is .

When does Karolinska Development pay dividends?

Karolinska Development pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Karolinska Development?

Karolinska Development paid dividends every year for the past 0 years.

What is the dividend of Karolinska Development?

For the upcoming 12 months, dividends amounting to 0 SEK are expected. This corresponds to a dividend yield of 0 %.

In which sector is Karolinska Development located?

Karolinska Development is assigned to the 'Health' sector.

Wann musste ich die Aktien von Karolinska Development kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Karolinska Development from 9/6/2024 amounting to 0 SEK, you needed to have the stock in your portfolio before the ex-date on 9/6/2024.

When did Karolinska Development pay the last dividend?

The last dividend was paid out on 9/6/2024.

What was the dividend of Karolinska Development in the year 2023?

In the year 2023, Karolinska Development distributed 0 SEK as dividends.

In which currency does Karolinska Development pay out the dividend?

The dividends of Karolinska Development are distributed in SEK.